Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Rebecca Kristeleit et al.|Cancer Discovery|2020Cited by 134
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Nicholas C. Turner, Sarah Hrebien et al.|Cancer Discovery|2020Cited by 67
517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumoursNatalie Cook, Ruth Plummer, Sarah P. Blagden et al.|Annals of Oncology|2021Cited by 10
Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Sarah P. Blagden et al.|Cancer Research|2024Cited by 3
719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Sarah P. Blagden et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2